Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis

Summary

The purpose of this phase III, multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Hemay005 compared to placebo as induction and maintenance therapy in Chinese participants with moderately to severely active ulcerative colitis.

Timeline

Start

2026-06

Primary completion

2028-05

Completion

2029-02

Drugs

Indications